Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.

Abstract

Eight weeks of treatment with rifampin-streptomycin sterilizes Mycobacterium ulcerans infection in mice. Because the bactericidal activity against M. ulcerans of the combination rifampin-moxifloxacin, rifampin-clarithromycin, or moxifloxacin-clarithromycin was similar to that of rifampin-streptomycin, these combinations might be considered as alternative, orally administered combined regimens for treatment of Buruli ulcer in humans.

• Authors: Baohong Ji, Aurélie Chauffour, Jérôme Robert, Sébastien Lefrançois, Vincent Jarlier
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 51 Issue 10 Pg. 3737-9 (Oct 2007) ISSN: 0066-4804 [Print] United States
• PMID: 17664316 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Antibiotics, Antitubercular
• Aza Compounds
• Drug Combinations
• Fluoroquinolones
• Quinolines
• Clarithromycin
• Moxifloxacin
• Rifampin
• Streptomycin

Topics

• Animals
• Anti-Bacterial Agents (therapeutic use)
• Antibiotics, Antitubercular (therapeutic use)
• Aza Compounds (therapeutic use)
• Clarithromycin (therapeutic use)
• Colony Count, Microbial
• Drug Combinations
• Female
• Fluoroquinolones
• Foot (microbiology)
• Mice
• Mice, Inbred BALB C
• Moxifloxacin
• Mycobacterium Infections, Nontuberculous (drug therapy, microbiology)
• Mycobacterium ulcerans
• Quinolines (therapeutic use)
• Rifampin (therapeutic use)
• Streptomycin (therapeutic use)